Abstract
There has been considerable in vivo evidence that chemokine receptor CXCR4 and its endogenous ligand CXCL12 modulate some important physiological and pathophysiological processes, including cancer metastasis, angiogenesis, invasion, growth and progression. In this review we elucidate key aspects of CXCL12-CXCR4 signaling system with emphasis on peptide-based and small-molecule CXCR4 inhibitors.
Keywords: Chemokine, chemokine receptor, CXCR4, CXCL12, SDF-1, tumor, cancer, drugs, inhibitors, antagonists
Mini-Reviews in Medicinal Chemistry
Title: CXCR4 Receptor as a Promising Target for Oncolytic Drugs
Volume: 8 Issue: 11
Author(s): Yan Lavrovsky, Yan A. Ivanenkov, Konstantin V. Balakin, Darya A. Medvedeva and Alexandre V. Ivachtchenko
Affiliation:
Keywords: Chemokine, chemokine receptor, CXCR4, CXCL12, SDF-1, tumor, cancer, drugs, inhibitors, antagonists
Abstract: There has been considerable in vivo evidence that chemokine receptor CXCR4 and its endogenous ligand CXCL12 modulate some important physiological and pathophysiological processes, including cancer metastasis, angiogenesis, invasion, growth and progression. In this review we elucidate key aspects of CXCL12-CXCR4 signaling system with emphasis on peptide-based and small-molecule CXCR4 inhibitors.
Export Options
About this article
Cite this article as:
Lavrovsky Yan, Ivanenkov A. Yan, Balakin V. Konstantin, Medvedeva A. Darya and Ivachtchenko V. Alexandre, CXCR4 Receptor as a Promising Target for Oncolytic Drugs, Mini-Reviews in Medicinal Chemistry 2008; 8 (11) . https://dx.doi.org/10.2174/138955708785909907
DOI https://dx.doi.org/10.2174/138955708785909907 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Prostaglandin J2 Family and the Cardiovascular System
Current Vascular Pharmacology Antiviral Drugs that Target Cellular Proteins May Play Major Roles in Combating HIV Resistance
Current Pharmaceutical Design Potential Pathways for CNS Drug Delivery Across the Blood-Cerebrospinal Fluid Barrier
Current Pharmaceutical Design Targeted Therapies in Gynecologic Cancers
Current Cancer Drug Targets Coagulation and Cancer Therapy: The Potential of Natural Compounds
Current Genomics Editorial [Hot Topic: New Approaches to Treating Cancer: Medicinal Chemistry and Therapeutic Potential (Guest Editor: David J. Weber)]
Current Topics in Medicinal Chemistry Copper Chelation Chemistry and its Role in Copper Radiopharmaceuticals
Current Pharmaceutical Design Modulation of TRAIL-Induced Apoptosis by HDAC Inhibitors
Current Cancer Drug Targets Targeting SphK1 as a New Strategy against Cancer
Current Drug Targets TRPV1 Function in Health and Disease
Current Pharmaceutical Biotechnology Assessment of Gene Transfer Using Imaging Methodology
Current Genomics Meet Our Editorial Board Member
Current Cancer Therapy Reviews Drug-Lipid Membrane Interaction Mechanisms Revealed Through Molecular Simulations
Current Physical Chemistry Gene Therapy: The First Approved Gene-Based Medicines, Molecular Mechanisms and Clinical Indications
Current Molecular Pharmacology Oxidative Stress, Redox Signaling and Cancer Chemoresistance: Putting Together the Pieces of the Puzzle
Current Medicinal Chemistry Natural Naphthoquinones with Great Importance in Medicinal Chemistry
Current Organic Synthesis Synergism of Temozolomide, Metformin, and Epigallocatechin Gallate Promotes Oxidative Stress-Induced Apoptosis in Glioma Cells
Current Drug Therapy Essential Role of Gli Proteins in Glioblastoma Multiforme
Current Protein & Peptide Science Patent Selections:
Recent Patents on CNS Drug Discovery (Discontinued) Intracellular Routing of Cytotoxic Pancreatic-Type Ribonucleases
Current Pharmaceutical Biotechnology